Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spizef is a brand of cefuroxime, a second-generation cephalosporin antibiotic developed and manufactured by Orchid Chemicals and Pharma. It is utilized for the treatment of various bacterial infections, including those of the respiratory tract, urinary tract, skin, and soft tissues, as well as for surgical prophylaxis. The drug functions by binding to bacterial penicillin-binding proteins (PBPs), thereby inhibiting the transpeptidation step of peptidoglycan synthesis. This disruption of cell wall assembly leads to bacterial cell lysis and death. Spizef is available in two distinct forms: cefuroxime axetil for oral administration (tablets) and cefuroxime sodium for parenteral administration (intravenous or intramuscular injection).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Spizef.